Loading
NASDAQHealthcareMedical - Instruments & Supplies
Latest quote
$5.75
−$0.16 · -2.71%
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.
Latest quote
$5.75
−$0.16 · -2.71%
After-hours
$5.77
+$0.02 · +0.35%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.
Day range
Current $5.75
52-week range
Current $5.75
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
85
Deep Value
Sentiment
64
Bullish
Risk
66
High Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.
Day range
Current $5.75
52-week range
Current $5.75
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.08B USD | 1.12B USD | 1.12B USD | 1.13B USD | 1.17B USD |
| Cost of goods sold | 400.9M USD | 394.2M USD | 370.9M USD | 354.6M USD | 365M USD |
| Gross profit | 679.5M USD | 728.9M USD | 749.9M USD | 774.9M USD | 800M USD |
| Research and development | 21.5M USD | 78.8M USD | 85.2M USD | 65M USD | 63M USD |
| Selling, general, and administrative | 331.4M USD | 365.1M USD | 341.3M USD | 294.8M USD | 240.3M USD |
| Operating expenses | 350.2M USD | 554.7M USD | 520.3M USD | 396.8M USD | 308M USD |
| Interest expense | 107.3M USD | 112.3M USD | 107M USD | 46.2M USD | — |
| Depreciation and amortization | 40.7M USD | 36.2M USD | 32.6M USD | 31.7M USD | 38M USD |
| Operating income | 329.3M USD | 174.2M USD | 229.6M USD | 378.1M USD | 492M USD |
| Net income | 95.4M USD | 78.3M USD | 70.4M USD | 223.6M USD | 414.8M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$5.00
13.04% downsideAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
